{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:01:42Z","timestamp":1787893302300,"version":"build-2784847793"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","nmd-journal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.nmd.2024.07.004","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T09:33:37Z","timestamp":1720690417000},"page":"22-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Risk-benefit profile of onasemnogene abeparvovec in older and heavier children with spinal muscular atrophy type 1"],"prefix":"10.1016","volume":"42","author":[{"given":"Rebecca","family":"Finnegan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Manzur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinki","family":"Munot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Dhawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Murugan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirban","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Wraige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasantha","family":"Gowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vanegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Main","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emer","family":"O'Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Baranello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariacristina","family":"Scoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.nmd.2024.07.004_bib0001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2352-4642(21)00287-X","article-title":"Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study","volume":"6","author":"Wei\u00df","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.nmd.2024.07.004_bib0002","unstructured":"National Institute for Health and Care Excellence: risdiplam for treating spinal muscular atrophy. December 2023. Risdiplam for treating spinal muscular atrophy (nice.org.uk)"},{"key":"10.1016\/j.nmd.2024.07.004_bib0003","unstructured":"National Institute for Health and Care Excellence: nusinersen for treating spinal muscular atrophy. July 2019. Nusinersen for treating spinal muscular atrophy (nice.org.uk)"},{"key":"10.1016\/j.nmd.2024.07.004_bib0004","unstructured":"National Institute for Health and Care Excellence: onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy. April 2023. 1 Recommendations | Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy | Guidance | NICE"},{"issue":"9","key":"10.1016\/j.nmd.2024.07.004_bib0005","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1080\/14712598.2022.2066471","article-title":"Onasemnogene abeparvovec for the treatment of spinal muscular atrophy","volume":"22","author":"McMillan","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.nmd.2024.07.004_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.726468","article-title":"Recombinant adeno-associated virus serotype 9 gene therapy in spinal muscular atrophy","volume":"12","author":"Kotulska","year":"2021","journal-title":"Front Neurol."},{"key":"10.1016\/j.nmd.2024.07.004_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101997","article-title":"Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in na\u00efve patients with spinal muscular atrophy and following switch from other therapies","volume":"59","author":"Pane","year":"2023","journal-title":"EClinicalMedicine."},{"key":"10.1016\/j.nmd.2024.07.004_bib0008","article-title":"Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from 6 infusion centres in the United Kingdom","volume":"37","author":"Gowda","year":"2023","journal-title":"Lancet Reg Health Eur."},{"issue":"5","key":"10.1016\/j.nmd.2024.07.004_bib0009","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/hmg\/ddad192","article-title":"A transcriptomics-based drug repositioning approach to identify drugs with similar activities for the treatment of muscle pathologies in spinal muscular atrophy (SMA) models","volume":"33","author":"Hoolachan","year":"2024","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2024.07.004_bib0010","unstructured":"Safety and Efficacy of Intravenous OAV101 (AVXS-101) in pediatric patients with spinal muscular atrophy (SMA) (SMART). Identifier NCT04851873. 2021. www.clinicaltrial.gov\/study\/NCT04851873"},{"key":"10.1016\/j.nmd.2024.07.004_bib0011","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejpn.2020.07.001","article-title":"European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy","volume":"28","author":"Kirschner","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.nmd.2024.07.004_bib0012","unstructured":"Efficacy and safety of intrathecal OAV101 (AVXS-101) in pediatric patients with type 2 spinal muscular atrophy (SMA) (STEER). Identifier NCT05089656. 2022. www.clinicaltrials.gov\/study\/NCT05089656"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896624001457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896624001457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T06:19:11Z","timestamp":1736230751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896624001457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":12,"alternative-id":["S0960896624001457"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2024.07.004","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk-benefit profile of onasemnogene abeparvovec in older and heavier children with spinal muscular atrophy type 1","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2024.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}